Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: Analysis of women in the control arm of the randomized, controlled PATRICIA trial

X Castellsagué; J Paavonen; U Jaisamrarn; CM Wheeler; SR Skinner; M Lehtinen; P Naud; SN Chow; MR Del Rosario-Raymundo; JC Teixeira; J Palmroth; NS De Carvalho; MJV Germar; K Peters; SM Garland; A Szarewski; WAJ Poppe; B Romanowski; TF Schwarz; WAA Tjalma; FX Bosch; MC Bozonnat; F Struyf; G Dubin; D Rosillon; L Baril; I Denham; A Mindel; P De Sutter; FY Aoki; F Diaz-Mitoma; M Dionne; L Ferguson; M Miller; K Papp; B Ramjattan; PH Orr; R Somani; D Apter; T Karppa; N Kudjoi; L Kyha-österlund; K Lönnberg; T Lunnas; T Petaja; M Vilkki; T Gent; T Grubert; W D Höpker; K Schulze; J Salmerón; C Crisostomo; JE Raymundo; G Limson; C Remollino; G Villanueva; S Villanueva; JD Zamora; J Bajo-Arenas; J Bayas; M Campins; M Castro; C Centeno; ML Rodríguez de la Pinta; A Torné; JA Vidart; MH Yu; S Angsuwathana; M Cruickshank; E A Hakim; H Kitchener; D Lewis; R Ackerman; M Caldwell; C Chambers; A Chatterjee; L DeMars; L Downs; D Ferris; P Fine; J Hedrick; W Huh; T Klein; J Lalezari; S Luber; M Martens; C Peterson; J Rosen; L Seidman; M Sperling; R Sperling; M Stager; J Stapleton; K Swenson; C Thoming; L Twiggs; A Waldbaum

Journal article

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: Analysis of women in the control arm of the randomized, controlled PATRICIA trial

X Castellsagué, J Paavonen, U Jaisamrarn, CM Wheeler, SR Skinner, M Lehtinen, P Naud, SN Chow, MR Del Rosario-Raymundo, JC Teixeira, J Palmroth, NS De Carvalho, MJV Germar, K Peters, SM Garland, A Szarewski, WAJ Poppe, B Romanowski, TF Schwarz, WAA Tjalma Show all

BMC Infectious Diseases | Published : 2014

DOI: 10.1186/s12879-014-0551-y

Download PDF

Abstract

Background: More information is needed about time between sexual initiation and human papillomavirus (HPV) infection and development of cervical precancer. Methods: The objectives were to investigate the time between first sexual activity and detection of first cervical HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15-25 years with no more than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to control, but only women from the control arm who began sexual intercourse during the study or wit..

View full abstract

University of Melbourne Researchers

Suzanne Wark Author

Grants

Funding Acknowledgements

This work was supported by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis (ClinicalTrials.gov Identifier: NCT00122681). GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and the publishing of the present manuscript.-CERVARIX is a registered trademark of the GlaxoSmithKline group of companies.